Pfizer has reached a settlement with the U.S. Securities and Exchange Commission (SEC) to receive $29 million from a dedicated recovery fund. The payment originates from a $602 million fund established following an insider trading scandal involving a unit of Steven Cohen's hedge fund. Pfizer successfully asserted its status as a victim in the scheme, which involved the misuse of the pharmaceutical giant's confidential information. This settlement concludes a long-standing legal dispute over the distribution of the remaining funds within the SEC's recovery pool. While the recovery provides a minor positive cash inflow, the amount is considered financially insignificant relative to Pfizer's overall scale and market capitalization. The resolution marks the end of a legal chapter tied to one of the most high-profile insider trading cases in recent history.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis